Patient Out-of-Pocket Payments for Oral Oncolytics: Results From a 2009 US Claims Data Analysis
Out-of-pocket payments differ widely among oral oncolytic options. As cost for therapy becomes a greater part of treatment decisions, an understanding of patient out-of-pocket cost will be critical in informing choices.
Impact of Persistence With Infliximab on Hospitalizations in Ulcerative Colitis
Therapeutic persistence with infliximab was associated with signifi cantly fewer ulcerative colitis patients requiring hospitalization; once hospitalized, patients with therapeutic persistence had significantly decreased inpatient costs.